{"id":"low-dose-oxcarbazepine","safety":{"commonSideEffects":[{"rate":"2-3%","effect":"Hyponatremia"},{"rate":"20-30%","effect":"Dizziness"},{"rate":"15-25%","effect":"Somnolence"},{"rate":"10-15%","effect":"Headache"},{"rate":"5-10%","effect":"Ataxia"},{"rate":"10-15%","effect":"Nausea"},{"rate":"5-10%","effect":"Diplopia"}]},"_chembl":{"chemblId":"CHEMBL1068","moleculeType":"Small molecule","molecularWeight":"252.27"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Oxcarbazepine is an anticonvulsant that primarily works by blocking voltage-dependent sodium channels, which stabilizes neuronal membranes and reduces repetitive neuronal firing. At low doses, it may also modulate high-voltage-activated calcium channels. The drug is a keto-analog of carbamazepine with a similar mechanism but potentially improved tolerability profile.","oneSentence":"Low-dose oxcarbazepine reduces neuronal excitability by blocking voltage-gated sodium channels and modulating calcium channels in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:53:17.525Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Epilepsy (adjunctive or monotherapy)"},{"name":"Neuropathic pain"},{"name":"Bipolar disorder (off-label use)"}]},"trialDetails":[{"nctId":"NCT03689114","phase":"PHASE4","title":"Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed, Previously Untreated Epilepsy(STANDLOW)","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2021-05-10","conditions":"Epilepsies, Partial","enrollment":58}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":78,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Low oxcarbazepine"],"phase":"marketed","status":"active","brandName":"Low dose oxcarbazepine","genericName":"Low dose oxcarbazepine","companyName":"Mario Negri Institute for Pharmacological Research","companyId":"mario-negri-institute-for-pharmacological-research","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Low dose oxcarbazepine is not mentioned in the provided facts, but low dose carbamazepine and low dose levetiracetam are being studied in clinical trials for newly diagnosed, previously untreated epilepsy. The efficacy and tolerability of low dose oxcarbazepine are not specified in the provided facts.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}